RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...

FDA drug alerts in infectious diseases, including new drug approvals, safety warnings, recalls, and changes in indications.

At the ongoing International Society for Stem Cell Research meeting, Chinese researchers reported they demonstrated that SPT6 homolog, histone chaperone and transcription elongation factor (SPT6) ...